These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 35863023)

  • 1. Proton Pump Inhibitor-Induced Gut Dysbiosis Increases Mortality Rates for Patients with Clostridioides difficile Infection.
    Lin CY; Cheng HT; Kuo CJ; Lee YS; Sung CM; Keidan M; Rao K; Kao JY; Hsieh SY
    Microbiol Spectr; 2022 Aug; 10(4):e0048622. PubMed ID: 35863023
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 2'-Fucosyllactose inhibits proliferation of
    Wiese M; Schuren FHJ; Smits WK; Kuijper EJ; Ouwens A; Heerikhuisen M; Vigsnaes L; van den Broek TJ; de Boer P; Montijn RC; van der Vossen JMBM
    Front Cell Infect Microbiol; 2022; 12():991150. PubMed ID: 36389156
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Proton Pump Inhibitor Omeprazole Does Not Promote Clostridioides difficile Colonization in a Murine Model.
    Tomkovich S; Lesniak NA; Li Y; Bishop L; Fitzgerald MJ; Schloss PD
    mSphere; 2019 Nov; 4(6):. PubMed ID: 31748246
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Battaglioli EJ; Hale VL; Chen J; Jeraldo P; Ruiz-Mojica C; Schmidt BA; Rekdal VM; Till LM; Huq L; Smits SA; Moor WJ; Jones-Hall Y; Smyrk T; Khanna S; Pardi DS; Grover M; Patel R; Chia N; Nelson H; Sonnenburg JL; Farrugia G; Kashyap PC
    Sci Transl Med; 2018 Oct; 10(464):. PubMed ID: 30355801
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diarrheal-associated gut dysbiosis in cancer and inflammatory bowel disease patients is exacerbated by
    Kulecka M; Zeber-Lubecka N; Bałabas A; Czarnowski P; Bagińska K; Głowienka M; Kluska A; Piątkowska M; Dąbrowska M; Waker E; Mikula M; Ostrowski J
    Front Cell Infect Microbiol; 2023; 13():1190910. PubMed ID: 37577378
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Domestic canines do not display evidence of gut microbial dysbiosis in the presence of Clostridioides (Clostridium) difficile, despite cellular susceptibility to its toxins.
    Stone NE; Nunnally AE; Jimenez V; Cope EK; Sahl JW; Sheridan K; Hornstra HM; Vinocur J; Settles EW; Headley KC; Williamson CHD; Rideout JR; Bolyen E; Caporaso JG; Terriquez J; Monroy FP; Busch JD; Keim P; Wagner DM
    Anaerobe; 2019 Aug; 58():53-72. PubMed ID: 30946985
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Composition of gut microbiota in patients with toxigenic Clostridioides (Clostridium) difficile: Comparison between subgroups according to clinical criteria and toxin gene load.
    Han SH; Yi J; Kim JH; Lee S; Moon HW
    PLoS One; 2019; 14(2):e0212626. PubMed ID: 30785932
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diluted Fecal Community Transplant Restores Clostridioides difficile Colonization Resistance to Antibiotic-Perturbed Murine Communities.
    Lesniak NA; Tomkovich S; Henry A; Taylor A; Colovas J; Bishop L; McBride K; Schloss PD
    mBio; 2022 Aug; 13(4):e0136422. PubMed ID: 35913161
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intestinal Dysbiosis and Risk of Posttransplant Clostridioides difficile Infection in a Longitudinal Cohort of Liver Transplant Recipients.
    Gomez-Simmonds A; Annavajhala MK; Nunez MP; Macesic N; Park H; Uhlemann AC
    mSphere; 2022 Oct; 7(5):e0036122. PubMed ID: 36135360
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proton pump inhibitors and risk for recurrent Clostridium difficile infection among inpatients.
    Freedberg DE; Salmasian H; Friedman C; Abrams JA
    Am J Gastroenterol; 2013 Nov; 108(11):1794-801. PubMed ID: 24060760
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of the gut microbiome of patients with
    Vázquez-Cuesta S; Villar L; García NL; Fernández AI; Olmedo M; Alcalá L; Marín M; Muñoz P; Bouza E; Reigadas E
    Front Cell Infect Microbiol; 2023; 13():1130701. PubMed ID: 37124040
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disordered Intestinal Microbial Communities During
    Chen Y; Lv T; Yan D; Zheng L; Zheng B; Wang J; Gu S; Li L
    Front Cell Infect Microbiol; 2022; 12():825189. PubMed ID: 35433508
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gut microbiota in burned patients with Clostridioides difficile infection.
    Shoaei P; Shojaei H; Siadat SD; Moshiri A; Vakili B; Yadegari S; Ataei B; Khorvash F
    Burns; 2022 Aug; 48(5):1120-1129. PubMed ID: 34924229
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation of Clinical Severity With Stool Microbiome Changes in Clostridioides difficile Infection.
    Castañeda-Mogollón D; Doolan CP; Toppings NB; Amarasekara R; Tran TA; Pillai DR
    Arch Pathol Lab Med; 2023 Jul; 147(7):774-785. PubMed ID: 36308712
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence of Clostridium difficile infection in patients receiving high-risk antibiotics with or without a proton pump inhibitor.
    Gordon D; Young LR; Reddy S; Bergman C; Young JD
    J Hosp Infect; 2016 Feb; 92(2):173-7. PubMed ID: 26616410
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of Intestinal Mycobiota of Patients with Clostridioides difficile Infection among a Prospective Inpatient Cohort.
    Cao Y; Wang L; Ke S; Kelly CP; Pollock NR; Villafuerte Gálvez JA; Daugherty K; Xu H; Yao J; Chen Y; Liu YY; Chen X
    Microbiol Spectr; 2022 Aug; 10(4):e0136222. PubMed ID: 35867408
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vonoprazan poses no additional risk of developing Clostridioides difficile infection compared to proton pump inhibitors.
    Saruta Y; Watanabe K; Tsuji T; Takahashi Y; Matsuzawa H; Yoshida T; Takahashi S; Shimodaira Y; Matsuhashi T; Iijima K
    J Gastroenterol Hepatol; 2023 Jun; 38(6):940-947. PubMed ID: 36882162
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Microbiome profile and calprotectin levels as markers of risk of recurrent
    Vázquez-Cuesta S; Lozano García N; Fernández AI; Olmedo M; Kestler M; Alcalá L; Marín M; Bermejo J; Díaz FF; Muñoz P; Bouza E; Reigadas E
    Front Cell Infect Microbiol; 2023; 13():1237500. PubMed ID: 37780848
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intestinal Dysbiosis Secondary to Proton-Pump Inhibitor Use.
    Naito Y; Kashiwagi K; Takagi T; Andoh A; Inoue R
    Digestion; 2018; 97(2):195-204. PubMed ID: 29316555
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile Infection.
    Khanna S; Assi M; Lee C; Yoho D; Louie T; Knapple W; Aguilar H; Garcia-Diaz J; Wang GP; Berry SM; Marion J; Su X; Braun T; Bancke L; Feuerstadt P
    Drugs; 2022 Oct; 82(15):1527-1538. PubMed ID: 36287379
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.